Drawing for SILPHION

USPTO serial 79062134

SILPHION

Reviewed by CopyMark Law Group

Reg. 3731578Status 404
Filing date
Status date
Registration date
Dec 29, 2009
Examiner
BRADLEY, EVELYN
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SILPHION?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

ANN LAMPORT HAMMITTE

ANN LAMPORT HAMMITTE LOWRIE, LANDO & ANASTASI, LLPRIVERFRONT OFFICE PARKONE MAIN STCAMBRIDGE, MA 02142

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations and medicines for human purposes, namely, antidotes to counteract poison, neurological and cardiovascular pharmaceuticals, antidepressants, antispasmodics, pain relief medication, nausea and vomiting treatment medications, vitamins, anti-cancer preparations, pediatric agents for treatment of conditions of the central nervous system, chromodiagnostics for the treatment of conditions of the central nervous system, cystic fibrosis treatment medicationsSECTION 71 - CANCELLED—
010Surgical and medical apparatus for administration of pharmaceuticals, namely, devices for delivery of pharmaceuticals by infusion, inhalation, injection; devices for delivery of pharmaceuticals via buccal, nasal, transdermal and transcorneal routes; structural parts and fittings for the aforesaid goodsSECTION 71 - CANCELLED—
042Research and development of pharmaceuticals, namely, development of new methods of packaging and delivery of pharmaceuticals, development of new clinical uses for drugs and research in the use of new and known pharmaceuticals; analysis of pharmaceutical compounds, namely, development, testing, inspection and research of pharmaceuticalsSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 7, 2019DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED—
Jun 7, 2019DETHDEATH OF INTERNATIONAL REGISTRATION—
May 20, 2017INNTTOTAL INVALIDATION PROCESSED BY THE IB—
May 19, 2017NREPNEW REPRESENTATIVE AT IB RECEIVED—
Apr 6, 2017INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Apr 5, 2017INPCINVALIDATION PROCESSED—
Apr 5, 2017INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Aug 5, 2016C71TCANCELLED SECTION 71—
Feb 6, 2013FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Oct 30, 2010NREPNEW REPRESENTATIVE AT IB RECEIVED—
Apr 23, 2010FICSFINAL DISPOSITION NOTICE SENT TO IB—
Apr 23, 2010FIMPFINAL DISPOSITION PROCESSED—
Mar 29, 2010FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Dec 29, 2009R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 13, 2009PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 23, 2009NPUBNOTICE OF PUBLICATION—
Sep 10, 2009PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Sep 9, 2009CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 31, 2009ACECAMENDMENT FROM APPLICANT ENTERED—
Aug 31, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 21, 2009MAILPAPER RECEIVED—
Jun 4, 2009CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 4, 2009CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 21, 2009ACECAMENDMENT FROM APPLICANT ENTERED—
May 21, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 19, 2009ALIEASSIGNED TO LIE—
May 18, 2009MAILPAPER RECEIVED—
Mar 14, 2009RFNTREFUSAL PROCESSED BY IB—
Feb 17, 2009RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Feb 17, 2009RFRRREFUSAL PROCESSED BY MPU—
Feb 14, 2009RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 13, 2009CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 7, 2009DOCKASSIGNED TO EXAMINER—
Dec 19, 2008MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 15, 2008NWAPNEW APPLICATION ENTERED—
Dec 12, 2008REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance